Skip to main content

Table 1 Clinical characteristic of patients with COVID-19 in the corticosteroid therapy and no corticosteroid therapy groups

From: Corticosteroid therapy in critically ill patients with COVID-19: a multicenter, retrospective study

  Total, n = 294 Corticosteroids, n = 183 No corticosteroids, n = 111 p value
Age, years 66 (56–75) 65 (56, 73) 67 (56, 78.5) 0.14
Male Sex 197 (67%) 151 (68%) 73 (66%) 0.91
Comorbidity     
 Hypertension 134 (46%) 82 (45%) 52 (47%) 0.83
 Diabetes 80 (27%) 53 (29%) 27 (24%) 0.47
 Heart disease 68 (23%) 40 (22%) 28 (25%) 0.6
 Chronic lung disease 36 (12%) 28 (15%) 8 (7%) 0.062
 Cerebrovascular disease 31 (11%) 15 (8%) 16 (14%) 0.14
 Immunosuppression 14 (5%) 7 (3%) 7 (10%) 0.047
PEEP,cmH2O 9 (6, 10) 8 (6, 10) 10 (6, 11) 0.56
PaO2/FiO2, mmHg 138 (86.5–204) 119.5 (80, 181.5) 176 (108, 260) < 0.001
Platequ pressure, cmH2O 25 (21–26) 25 (22.5, 28) 25 (21, 26) 0.057
Mean arterial pressure, mmHg 90 (80–97) 90 (81, 97) 90 (80, 97) 0.7
Creatinine, μmol/L 76 (61.7–101.2) 76.35 (63.7, 100.8) 72.65 (56.3, 103.4) 0.24
Elevated TnI, 95 (41%) 52 (35%) 43 (51%) 0.024
Bilirubin, μmol/L 22.2 (13.2–24) 23 (14.72, 24) 21 (10.9, 24) 0.028
Platelet count, × 109/L 158 (114–207.3) 154 (113, 197.3) 168.1 (118.3, 229.8) 0.1
Lymphocyte percentage, % 6.2 (2.6–11.3) 5.4 (2.1, 10.11) 7.2 (3.8, 15.3) 0.006
APACHEII score 14.5 (11, 18) 15 (11, 18) 13 (11, 17) 0.35
SOFA score 4 (3–5.75) 4 (3, 6) 3 (2, 5) 0.005
Complication     
 Shock 121 (42%) 83 (46%) 38 (35%) 0.076
 ARDS 214 (74%) 146 (81) 68 (62%) < 0.001
 AKI 90 (31%) 61 (34%) 29 (26%) 0.24
 Secondary infection, 44 (15%) 34 (19%) 10 (9%) 0.039
Respiratory support received     
 Mechanical ventilation 230 (78.2%) 148 (80.8%) 82 (73.9%) 0.031
 Prone 46 (16%) 31 (17%) 15 (14%) 0.56
 ECMO 21 (7%) 17 (9%) 4 (4%) 0.1
 Tracheotomy 23 (8%) 13 (7%) 10 (9%) 0.72
 Requirement of CRRT 40 (14%) 26 (14%) 14 (13%) 0.83
Symptom onset to hospital admission, day 7(4–10) 7(4–10) 7 (3–14) 0.13
Symptom onset to ICU admission, day 11 (7–17) 11 (7.5, 16) 11 (6.5, 21) 0.91
Duration of ventilation, day 7 (0, 13) 8 (2, 15) 3 (0, 10) < 0.001
ICU length of stay, day 13 (7–22) 13.5(8–23) 13 (5–20) 0.57
Hospital length of stay, day 20 (12–32) 21 (12.5–33) 17.5 (21–31) 0.34
90-day mortality 146 (50%) 97 (53%) 49 (44%) 0.18
Time to RNA clearance among 90-day survivors, day 9 (3–17) 10 (5, 17.5) 7 (1, 15) 0.049
  1. Immunosuppression was defined as human immunodeficiency virus infection, malignancy, chemotherapy or organ transplantation. Laboratory and ventilator parameters on Day 1 of ICU admission were presented. Data presented as n (%) or median (Q1–Q3)
  2. PEEP positive end-expiratory pressure, Q quartile, SOFA Sequential Organ Failure Assessment, APACHEII acute physiology and chronic health evaluation, Tnl Troponin I, ECMO extracorporeal membrane oxygenation, ARDS adult respiratory distress syndrome, AKI acute kidney injury